A5017872517- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Pulmonary Hypertension Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Cancer Treatment and Pharmacology
- Lipoproteins and Cardiovascular Health
- Hormonal Regulation and Hypertension
- Cardiac electrophysiology and arrhythmias
- Diabetes Treatment and Management
- Ultrasound in Clinical Applications
- Cardiovascular Effects of Exercise
- GDF15 and Related Biomarkers
- Cardiovascular Disease and Adiposity
- Cardiac Fibrosis and Remodeling
- Signaling Pathways in Disease
- Cardiovascular and exercise physiology
- Heart Rate Variability and Autonomic Control
- Atherosclerosis and Cardiovascular Diseases
- Education, Innovation and Language Studies
- Apelin-related biomedical research
- Histone Deacetylase Inhibitors Research
National Medical Research Center of Cardiology
2017-2025
Moscow State University of Medicine and Dentistry
2021-2025
Ministry of Health of the Russian Federation
2025
Institute of Experimental Cardiology
2008-2015
Russian Society of Cardiology (RSC) With the participation: National Myocardial Diseases and Heart Failure, Failure Specialists, Scientific Medical Internal Medicine Endorsed by Research Practical Council Ministry Health Federation (12.09.2024)
The adult heart contains small populations of multipotent cardiac progenitor cells (CPC) that present a convenient and efficient resource for treatment myocardial infarction. Several clinical studies direct CPC delivery by injection have already been performed but showed low engraftment rate limited beneficial effects procedure. «Cell sheet» technology has developed to facilitate longer retention grafted show new directions cell-based therapy using this strategy. In study we hypothesized...
Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure (HF) with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties statins, such as anti-inflammatory, antihypertrophic, antifibrotic, antioxidant effects, generally accepted may be beneficial HF, especially HFpEF. Numerous observational clinical trials have consistently shown a prognostic effect statins patients HFpEF,...
Abstract Aims The purpose of this pilot study was to assess the potential usefulness diastolic stress test (DST) echocardiography in patients with suspected heart failure preserved ejection fraction (HFpEF). Methods and results Patients HFpEF (left ventricular ≥ 50%, exertional dyspnoea, septal E/e′ at rest 9–14, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) < 220 pg/mL; n = 13) a control group constituted from asymptomatic arterial hypertension ( 19) healthy subjects 18) were...
Heart failure with preserved ejection fraction (HFpEF) is frequently complicated by pulmonary hypertension (PH). A vascular contribution could be considered as a substantial therapeutic target in HFpEF and PH combined pre- postcapillary (Cpc-PH).We enrolled 50 patients Cpc-PH who were determined echocardiography to have artery systolic pressure (PASP) > 40 mmHg, resistance 3 Wood units, and/or transpulmonary gradient 15 mmHg.The assigned the phosphodiesterase 5 (PDE5) inhibitor sildenafil...
Relevant aspects of the pathogenesis, diagnosis, And treatment heart failure with preserved LV EFThis review analyzes results studies recent decade that focus on epidemiology, mechanisms development, diagnostic methods, and treatments ejection fraction (HFpEF). As expected, prevalence HFpEF continues to increase due growing contribution comorbidities structure causes for chronic (CHF), such as arterial hypertension left ventricular hypertrophy, obesity, kidney disease, well ageing population...
Heart failure with preserved ejection fraction (HFpEF) remains a significant challenge in modern healthcare. It accounts for the majority of heart cases and their number worldwide is steadily increasing. With its high prevalence substantial clinical impact, therapeutic strategies HFpEF are still inadequate. This review focuses on cardiometabolic phenotype which characterized by such conditions as obesity, type 2 diabetes mellitus hypertension. Various murine models that mimic this discussed....
Clinical trials have established the prognostic benefits of sodium‒glucose cotransporter 2 (SGLT2) inhibitors in patients with type diabetes mellitus (T2DM) and heart failure (HF) preserved ejection fraction (HFpEF), although underlying mechanisms are not clearly understood. The purpose this study was to determine effects SGLT2 inhibitor empagliflozin on functional capacity, left ventricular (LV) diastolic function/filling pressure, cardiac reserves HFpEF T2DM. In present prospective...
Among the main priorities of healthcare system is problem chronic heart failure (CHF). It critically important to assess and reduce incidence CHF, improve treatment patients with increase duration quality their life, related financial burden. One approaches for monitoring medical care in CHF conducting a large, long-term observational registry study involving multiple organizations, inclusion maximum number documented assessing continuity, diagnosis treatment, adherence possibility...
Diagnosis of heart failure with preserved ejection fraction (HFpEF) is associated certain difficulties since many patients HFpEF have a slight left ventricular diastolic dysfunction and normal filling pressure at rest. improved by using transthoracic stress-echocardiography dosed exercise (or stress test), which allows detection increased during the exercise. The present expert consensus explains requirement for test in diagnosing from clinical pathophysiological standpoints; defines...
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) heart failure a preserved ejection fraction (HFpEF). Monocytes T-helpers (Th) involved both pro-inflammatory fibrotic processes, while regulatory T-cells (Treg) could be considered to suppress chronic the hypertrophied myocardium. We aimed estimate relationship between frequencies of circulating CD4+ T-cell monocyte subpopulations variables (LV) diastolic...
Heart failure withpreserved ejection fraction (HFpEF) is a severe disease with an often unfavorable outcome. The prevalence of HFpEF continues to increase, while effective treatment options remain elusive. All the medical strategies used toimprove outcome in heart reduced proved ineffective HFpEF, which was probably due different mechanisms ofdevelopment these two types and diversity phenotypes. According current paradigm development, chronic mild pro-inflammatory statecauses coronary...
The article discusses the problem of improving effectiveness treatment heart failure with preserved left ventricular ejection fraction (HFpEF). relative "failure" early studies renin-angiotensin-aldosterone system inhibitors was largely due to lack understanding that patients HFpEF represent a heterogeneous group various etiological factors and pathogenetic mechanisms disease. Therefore, so-called personalized approach should be used in these patients. This is based on identification clearly...
Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties statins, such as anti-inflammatory, antihypertrophic, antifibrotic, antioxidant effects, generally accepted may be beneficial HF, especially HFpEF. Numerous observational clinical trials have consistently shown a prognostic effect statins patients HFpEF, while...
The document focuses on key issues of diuretic therapy in CHF from the standpoint current views pathogenesis edema syndrome, its diagnosis, and characteristics using diuretics various clinical situations.
(1) Background: The structural and functional features of the natural history asymptomatic hypertensive left ventricular hypertrophy (LVH) are not clearly defined. (2) Objective: To determine changes in LVH, as well incidence predictors transition to different phenotypes heart failure (HF) after a long-term follow-up. (3) Methods: Based on assessment chart reviews, we retrospectively selected 350 patients with concentric LVH LV ejection fraction (EF) ≥ 50%. After median follow-up 8.1 years,...
Heart failure withpreserved ejection fraction (HFpEF) is a severe disease with an often unfavorable outcome. The prevalence of HFpEF continues to increase, while effective treatment options remain elusive. All the medical strategies used toimprove outcome in heart reduced proved ineffective HFpEF, which was probably due different mechanisms ofdevelopment these two types and diversity phenotypes. According current paradigm development, chronic mild pro-inflammatory statecauses coronary...
This document is a consensus of Russian Specialists in Heart Failure, Society Cardiology, Association Ultrasound Diagnostics Medicine and for the Prevention Noncommunicable Diseases. In definition focus ultrasound stated discussed when it can be used cardiology practice Federation.
The article focuses on modern views the role and place of left ventricular ejection fraction (LV EF) in determining status cardiovascular patients (primarily with heart failure) algorithm for their diagnosis, treatment, prediction outcome. Conclusions recommendations use LV EF chronic failure (CHF) are following: 1) remains a familiar convenient instrumental indicator not so much myocardial contractility as hemodynamics general. Assessment is useful selection ranking CHF whereas dynamics...
Objective: Reduced cardiac reserves play an important role in poor exercise tolerance heart failure with preserved ejection fraction (HFpEF). However, their prognostic HFpEF is not well defined. We aimed to evaluate the significance of key patients HFpEF. Design and method: 348 (164 men, median age 68 years) stable NYHA functional class II-III, left ventricular (LV) (>=50%), increased LV filling pressure at rest and/or during (determined by echocardiography) were included retrospective...